Hi, Thank you for your query. I can understand your concerns. Cymbalta (duloxetine hydrochloride) is a selective serotonin and norepinephrine reuptake inhibitor (SSNRI) for oral administration.The recommended dose for Cymbalta is 60 mg orally once daily. Symptoms associated with discontinuation of Cymbalta have been reported. A gradual reduction in the dose rather than abrupt cessation is recommended whenever possible. Following tapered discontinuation in placebo-controlled clinical trials, the following symptoms occurred at 1% or greater and at a significantly higher rate in duloxetine-treated patients compared to those discontinuing from placebo: dizziness, headache, nausea, diarrhea, paresthesia, irritability, vomiting, insomnia, anxiety, hyperhidrosis, and fatigue. Patients should be monitored for these symptoms when discontinuing treatment with Cymbalta. If intolerable symptoms occur following a decrease in the dose or upon discontinuation of treatment, then resuming the previously prescribed dose may be considered. Subsequently, the physician may continue decreasing the dose but at a more gradual rate. Regards Dr. T.K. Biswas M.D. Mumbai